Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Debio 0328

Drug Profile

Debio 0328

Alternative Names: [68Ga]Ga-DPI-4452; Debio-0328; Gallium-68 DPI 4452

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3B Pharmaceuticals
  • Developer Debiopharm
  • Class Antineoplastics; Cyclic peptides; Imaging agents; Peptide diagnostics; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Pancreatic cancer; Renal cell carcinoma

Most Recent Events

  • 25 Jan 2024 Efficacy and adverse events data from a phase I/II clinical trials in Renal cell carcinoma, Pancreatic cancer, Colorectal cancer presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)
  • 14 Mar 2023 Phase-I/II clinical trials in Colorectal cancer (In adults, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in France (IV) (NCT05706129)
  • 14 Mar 2023 Phase-I/II clinical trials in Pancreatic cancer (In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In adults) in France (IV) (NCT05706129)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top